Medical affairs has evolved from a support function into a strategic pillar of pharmaceutical commercialization. As the industry's engagement model with the medical community has shifted away from promotional messaging toward scientific exchange, medical affairs teams — and the consultants who advise them — have taken on broader responsibilities: KOL engagement strategy, real-world evidence communication, health economics and outcomes research dissemination, and MSL field force deployment optimization.
According to Pharma Intelligence's 2023 Medical Affairs Benchmarking Survey, pharmaceutical companies now allocate an average of 8 to 12 percent of their commercial budgets to medical affairs activities — up from 4 to 6 percent a decade ago. The consulting firms that advise these companies on medical affairs strategy and execution are correspondingly busy, and the administrative demands of that work are substantial.
KOL Identification, Database Management, and Engagement Coordination
Effective KOL strategy begins with comprehensive, current intelligence about opinion leaders in a therapeutic area: their publication records, clinical trial participation, congress presentations, speaking history, and affiliation networks. Building and maintaining KOL databases requires systematic literature monitoring, congress tracking, and data hygiene work.
Virtual assistants supporting medical affairs consulting firms can execute systematic PubMed and ClinicalTrials.gov searches to maintain KOL publication and trial participation records, track congress speaker and abstract presentation data, update KOL database entries as affiliations and institutional roles change, and compile formatted KOL profiles for client advisory board planning purposes.
Once KOL engagement plans are in motion, VAs can also manage the logistics: advisory board scheduling, contract and honoraria documentation coordination, travel arrangement support, and meeting material distribution. This allows medical affairs consultants to focus on the strategic dimension of KOL relationships rather than the operational choreography.
Publication Planning and Medical Writing Support Coordination
Publication planning is a core medical affairs function, and consulting firms frequently support clients in developing and executing publication strategies that position clinical and real-world evidence effectively with the medical community. Managing a publication plan — tracking manuscript timelines, coordinating author approvals, managing journal submission logistics, and maintaining the publication tracker — generates ongoing administrative volume.
Virtual assistants supporting publication planning can maintain the publication tracker database, follow up with authors and medical writers on draft review deadlines, compile journal submission documentation packages, track peer review response timelines, and distribute publication milestone reports to client stakeholders. According to Good Publication Practice (GPP3) guidelines, publication planning processes require documented accountability and timeline management — both of which are well-suited to systematic VA support.
MSL Program Administration and Field Force Support
Medical affairs consulting firms frequently advise on MSL (medical science liaison) program design, training, and performance management. These engagements involve field force documentation, KOL interaction report analysis, training material logistics, and meeting coordination that generates significant administrative output.
VAs supporting MSL-related consulting engagements can maintain KOL interaction report libraries, compile field force performance data for analysis, coordinate MSL training session logistics, and manage the document repository for MSL program design deliverables. This organizational support allows consultants to spend their time on program design strategy and client advisory rather than file management.
Scientific Communication Content Support
Medical affairs consulting firms often support clients in developing congress materials, disease awareness resources, and scientific platform documents. The research and content development process for these materials — pulling supporting data, formatting references, maintaining version control through review cycles, and coordinating medical-legal-regulatory review logistics — is time-consuming and detail-intensive.
Virtual assistants can support scientific communication projects by compiling reference libraries, formatting citation sections, maintaining version-controlled document files through MLR review cycles, and coordinating distribution of final approved materials to client teams. This frees medical writers and scientific consultants to focus on content strategy and accuracy rather than the administrative scaffolding around content development.
Medical affairs consulting firms looking to extend delivery capacity while maintaining the quality and responsiveness that clients expect should consider VA providers with pharmaceutical and life sciences backgrounds. Stealth Agents places VAs who are familiar with medical affairs terminology and consulting workflows, reducing the onboarding investment needed to get productive support running quickly.
Delivering More Without Hiring More
The economic model of a consulting firm rewards utilization — the proportion of billable work that senior consultants actually spend on strategic, client-facing activity. Every administrative hour that a senior medical affairs consultant spends on database maintenance, meeting logistics, or document tracking is an hour that is not being spent on the work that clients actually pay consulting rates for. Virtual assistants systematically redirect those hours, improving both delivery capacity and margin without requiring the firm to expand its senior headcount on every new client engagement.
Sources
- Pharma Intelligence, "Medical Affairs Benchmarking Survey" (2023)
- International Society for Medical Publication Professionals, "Good Publication Practice (GPP3) Guidelines" (2022 update)
- Informa Pharma Intelligence, "The Evolving Role of Medical Affairs in Pharmaceutical Commercialization" (2023)